CathVision has developed a new algorithmic tool (PFAnalyzer) to help physicians assess durable lesion during Pulsed Field Ablation (PFA). The PFAnalyzer™ module allows the EP to see and quantify local potential energy in the tissue after PFA for the first time, potentially improving both the safety and efficacy of this method. Dr. Ante Anic (University Clinical Hospital, Split Croatia) have received Ethics Committee approval in Split, Croatia, to initiate a first-in-human study with PFAnalyzer to begin early 3Q 2025. The EP lab in Split runs First-In-Human studies on a regular basis with an emphasis on development of pulsed field ablation.
CathVision’s PFAnalyzer’s preclinical study “Measurement of Unipolar Residual Signals Following Pulsed-Field Ablation (PFA)” was presented at Heart Rhythm Society’s 2025 meeting by Mt. Sinai New York City, led by Dr. Jacob Koruth, Dr. Vivek Reddy, and Dr. Keita Watanabe. The study confirmed that conventional bipolar voltage mapping is inadequate for validating isolation following pulsed field ablation (PFA).
“An easy-to-use, fast, and standardized validation of PFA lesion success, without adding procedural complexity, has the potential to solve the durability shortcomings that the literature continues to demonstrate. PFA needs to achieve optimized durability in the hands of most EPs,” said Dr. Jacob Koruth, The Mt. Sinai Hospital, New York City.
“With conventional EP mapping systems using traditional bipolar mapping, we cannot reliably see local signals from stunned or recoverable tissue immediately post-PFA. However, if signal quality and processing allow us to reveal these gaps, electrogram-based analysis can quickly scale to widespread clinical practice without requiring additional catheters or equipment,” said Dr. Jacob Koruth.
While PFA technology has been rapidly adopted as a preferred ablation technology due to speed advantages, lesion durability has become a focus. The EU-PORIA study re-mapped 149 patients admitted with AF recurrence for repeat ablation and found only 38% of patients had durable pulmonary vein isolation.